Wang Yingsong, Fang Tianxiang, Zheng Xiaoya, Huangfu Ning
Department of Cardiology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Health Science Center, Ningbo University, Ningbo, China.
Front Cardiovasc Med. 2025 Sep 4;12:1606034. doi: 10.3389/fcvm.2025.1606034. eCollection 2025.
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, largely driven by the progression of atherosclerotic plaques. In atherosclerosis (AS), transcription factors and epigenetic mechanisms play pivotal roles in regulating gene expression. Interferon regulatory factors (IRFs), a family of transcription factors initially identified for their role in coordinating interferon (IFN) responses, are now recognized as critical modulators of innate and adaptive immunity. Emerging evidences highlights their involvement in inflammation, lipid metabolism, cell differentiation, cell proliferation, and programmed cell death during AS pathogenesis. This review synthesizes current knowledge on the roles and regulatory mechanisms of IRFs in AS, offering novel insights and potential therapeutic targets for AS management.
心血管疾病(CVDs)仍然是全球发病和死亡的主要原因,主要由动脉粥样硬化斑块的进展所驱动。在动脉粥样硬化(AS)中,转录因子和表观遗传机制在调节基因表达中起关键作用。干扰素调节因子(IRFs)是一类最初因其在协调干扰素(IFN)反应中的作用而被鉴定的转录因子,现在被认为是先天和适应性免疫的关键调节因子。新出现的证据突出了它们在AS发病机制中的炎症、脂质代谢、细胞分化、细胞增殖和程序性细胞死亡过程中的参与。本综述综合了关于IRFs在AS中的作用和调节机制的当前知识,为AS的管理提供了新的见解和潜在的治疗靶点。